Excelsior Biopharma Inc. (TPEX:6496)

Market Cap	1.13B -5.4%
Revenue (ttm)	906.42M +2.8%
Net Income	-197.05M
EPS	-4.26
Shares Out	46.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,952
Open	23.70
Previous Close	24.25
Day's Range	23.70 - 24.35
52-Week Range	22.50 - 30.55
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Excelsior Biopharma

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmece...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6496

Financial Performance

In 2025, Excelsior Biopharma's revenue was 898.26 million, an increase of 4.22% compared to the previous year's 861.91 million. Losses were -183.17 million, 85.6% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 30, 2026

Data Sources Report a data error